公开(公告)号：US20100292247A1

公开(公告)日：2010-11-18

申请号：US12377911

申请日：2007-10-24

Applicant: Frederick Brookfield ,  Jonathan Gridley ,  Lothar Kling ,  Michael Prime ,  Ulrike Reiff ,  Wolfgang von der Saal ,  Thomas von Hirschheydt

Inventor： Frederick Brookfield ,  Jonathan Gridley ,  Lothar Kling ,  Michael Prime ,  Ulrike Reiff ,  Wolfgang von der Saal ,  Thomas von Hirschheydt

IPC: A61K31/496 ,  C07D401/14 ,  C07D401/04 ,  C07D491/113 ,  A61K31/438 ,  A61P35/00

CPC classification number: C07D295/04

Abstract: Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明的目的是式I化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物及其制备，以及上述化合物在对照中的用途 或预防癌症等疾病。

公开(公告)号：US07429605B2

公开(公告)日：2008-09-30

申请号：US11497145

申请日：2006-08-01

Applicant: Birgit Bossenmaier ,  Thomas Friess ,  Rolf Juchem ,  Lothar Kling ,  Irene Kolm ,  Hans-Willi Krell ,  Thomas von Hirschheydt ,  Edgar Voss

Inventor： Birgit Bossenmaier ,  Thomas Friess ,  Rolf Juchem ,  Lothar Kling ,  Irene Kolm ,  Hans-Willi Krell ,  Thomas von Hirschheydt ,  Edgar Voss

IPC: A61K31/4439 ,  C07D401/12

CPC classification number: C07D401/12

Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明涉及式I化合物：其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有这些化合物的药物组合物及其制备方法以及这些化合物在 控制或预防癌症等疾病。

公开(公告)号：US06911553B1

公开(公告)日：2005-06-28

申请号：US09675943

申请日：2000-09-29

Applicant: Angelika Esswein ,  Lothar Kling

Inventor： Angelika Esswein ,  Lothar Kling

IPC: C07F9/09 ,  C07F9/06

CPC classification number: C07F9/091

Abstract: The invention is directed to compounds of formula (I) wherein R1 alkyl, alkenyl or alkynyl having from 6 to 24 carbon atoms; n=0-12; X=oxygen or NH; and the physiologically safe salts, esters, optically active forms, racemates and derivatives thereof which can be metabolized in vivo to yield compounds of general formula (I), methods of preparing same, and drugs containing said compounds, for treating bone metabolic disorders.

Abstract translation: 本发明涉及式（I）化合物，其中R 1，R 2，R 2，R 2， n = 0-12; X =氧或NH; 以及其可在体内代谢产生通式（I）的化合物，其制备方法和含有所述化合物的药物用于治疗骨代谢紊乱的生理上安全的盐，酯，光学活性形式，外消旋体及其衍生物。

公开(公告)号：US20070123513A1

公开(公告)日：2007-05-31

申请号：US11594297

申请日：2006-11-08

Applicant: Lothar Kling ,  Ulrike Reiff ,  Manfred Schwaiger ,  Georg Tiefenthaler ,  Wolfgang von der Saal ,  Thomas von Hirschheydt

Inventor： Lothar Kling ,  Ulrike Reiff ,  Manfred Schwaiger ,  Georg Tiefenthaler ,  Wolfgang von der Saal ,  Thomas von Hirschheydt

IPC: A61K31/55 ,  A61K31/4439 ,  A61K31/4412 ,  A61K31/4545 ,  C07D213/63

CPC classification number: C07D213/71

Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明涉及式I化合物：其药学上可接受的盐，对映体形式，非对映异构体和外消旋体，这些化合物的制备，含有它们的药物组合物及其制备，以及这些化合物在控制或预防中的用途 的疾病，如癌症。

公开(公告)号：US20050267179A1

公开(公告)日：2005-12-01

申请号：US11132082

申请日：2005-05-18

Applicant: Birgit Bossenmaier ,  Walter-Gunar Friebe ,  Thomas Friess ,  Lothar Kling ,  Ulrike Reiff ,  Edgar Voss

Inventor： Birgit Bossenmaier ,  Walter-Gunar Friebe ,  Thomas Friess ,  Lothar Kling ,  Ulrike Reiff ,  Edgar Voss

IPC: A61K31/422 ,  A61P35/00 ,  C07D413/02 ,  C07D413/12

CPC classification number: C07D413/12

Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明的目的是式（I）化合物的药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物组合物及其制备方法，以及上述化合物在 控制或预防癌症等疾病。

公开(公告)号：US06809175B1

公开(公告)日：2004-10-26

申请号：US09509559

申请日：2000-11-27

Applicant: Wolf-Georg Forssmann ,  Ludger Standker ,  Markus Meyer ,  Hossein Mostafavi ,  Hans-Georg Opitz ,  Lothar Kling

Inventor： Wolf-Georg Forssmann ,  Ludger Standker ,  Markus Meyer ,  Hossein Mostafavi ,  Hans-Georg Opitz ,  Lothar Kling

IPC: C07K1400

CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K14/475

Abstract: A peptide referred to as cadherin-derived growth factor (CDGF) the sequence of which corresponds to a partial sequence of a pre-pro-cadherin, said pre-pro-cadherin comprising the domains signal sequence, pro sequence cadherin repeats, transmembrane region and intracellular domain, characterized in that the sequence of said peptide comprises the pro sequence, that at least one of the other domains of the pre-pro-cadherin is lacking, and that said peptide has cell-proliferative, cell-protective and/or cell-differential properties.

Abstract translation: 称为钙粘蛋白衍生生长因子（CDGF）的肽，其序列对应于前前钙粘蛋白的部分序列，所述前前钙粘蛋白包含结构域信号序列，前序列钙粘着蛋白重复序列​​，跨膜区和 细胞内结构域，其特征在于所述肽的序列包含前序列，所述前体前钙粘蛋白的至少一个其他结构域缺乏，并且所述肽具有细胞增殖，细胞保护和/或细胞 差分属性。

公开(公告)号：US06444832B1

公开(公告)日：2002-09-03

申请号：US09407981

申请日：1999-09-29

Applicant: Angelika Esswein ,  Lothar Kling ,  Ulrike Leser ,  Walter-Gunar Friebe

Inventor： Angelika Esswein ,  Lothar Kling ,  Ulrike Leser ,  Walter-Gunar Friebe

IPC: C07C23100

CPC classification number: C07C233/18 ,  C07C233/20

Abstract: Compounds of formula I in which R1 denotes hydrogen or methyl R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms R3 denotes hydrogen or lower alkyl n denotes 0-12 R4 denotes alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of osteoporosis.

Abstract translation: R1表示氢或甲基R2的式Iin化合物表示具有1至10个碳原子的较低直链或支链烷基R 3表示氢或低级烷基，表示0-12R 4表示具有6至24个碳原子的烷基，烯基或炔基，其制备方法 以及含有这些化合物用于治疗骨质疏松症的药剂。

公开(公告)号：US07005526B2

公开(公告)日：2006-02-28

申请号：US11132082

申请日：2005-05-18

Applicant: Birgit Bossenmaier ,  Walter-Gunar Friebe ,  Thomas Friess ,  Lothar Kling ,  Ulrike Reiff ,  Edgar Voss

Inventor： Birgit Bossenmaier ,  Walter-Gunar Friebe ,  Thomas Friess ,  Lothar Kling ,  Ulrike Reiff ,  Edgar Voss

IPC: C07D263/32 ,  C07D249/04 ,  A61K31/422 ,  A61K31/4192

CPC classification number: C07D413/12

Abstract: Objects of the present invention are the compounds of formula (I) formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.

Abstract translation: 本发明的目的是式（I）式（I）的化合物，化学式id =“CHEM-US-00001”num =“000

公开(公告)号：US06197759B1

公开(公告)日：2001-03-06

申请号：US09508714

申请日：2000-04-11

Applicant: Angelika Esswein ,  Lothar Kling

Inventor： Angelika Esswein ,  Lothar Kling

IPC: A61K31661

CPC classification number: C07F9/091

Abstract: Osteoblast-specific mitogens and drugs containing such compounds can be used for treating metabolic bone diseases. These compounds include lysophosphatidylic acid derivatives selected from the group consisting of compounds of formula: wherein R1=alkenyl or alkynyl having from 6 to 24 carbon atoms; n=0-12; X=oxygen or NH; the compounds (all-cis-5,8,11,14)-eicosatetraenoic acid 2-hydroxy-3-phosphonooxypropyl ester; cis-9, cis-12-octadecadienoic acid 2-hydroxy-3-phosphonooxypropyl ester; (all-cis-9,12,15)-octadecatrienoic acid 2-hydroxy-3-phosphonooxypropyl ester; cis-9-octadecenoic acid 2-hydroxy-3-phosphonooxypropyl ester; and erucic acid 2-hydroxy-3-phosphonooxypropylester being excluded, and the physiologically tolerable salts, esters, optically active forms, and racemates of said compounds, and derivatives of said compounds, salts, esters, optically active forms and racemates which can be metabolized in vivo to yield the corresponding compound of formula (I).

Abstract translation: 成骨细胞特异性有丝分裂原和含有此类化合物的药物可用于治疗代谢性骨病。 这些化合物包括选自下式的化合物的溶血磷脂酰衍生物：其中R1 =具有6至24个碳原子的烯基或炔基; n = 0-12; X =氧或NH;化合物（全顺式-5， 8,11,14） - 二十碳四烯酸2-羟基-3-膦酰氧基丙基酯; 顺式-9，顺式-12-十八碳二烯酸2-羟基-3-膦酰氧基丙基酯; （全顺式-9,12,15） - 十八碳三烯酸2-羟基-3-膦酰氧丙基酯; 顺-9-十八碳烯酸2-羟基-3-膦酰氧基丙酯; 和芥酸2-羟基-3-膦酰氧基丙基酯，以及所述化合物的生理上可耐受的盐，酯，旋光形式和外消旋物，以及所述化合物的衍生物，盐，酯，旋光活性物质和可被代谢的外消旋体 在体内产生相应的式（I）化合物。

公开(公告)号：US5486530A

公开(公告)日：1996-01-23

申请号：US380323

申请日：1995-01-30

Applicant: Tim Boelke ,  Lothar Kling ,  Reinhard Koenig

Inventor： Tim Boelke ,  Lothar Kling ,  Reinhard Koenig

IPC: A61K31/64 ,  A61K31/44

CPC classification number: A61K31/64

Abstract: Use of torasemide for the treatment of brain edemas and orally and parenterally administerable torasemide.

Abstract translation: 使用托拉塞米治疗脑水肿，口服和肠胃外施用托拉塞米。